Oceania · News · The Mercury

Alterity’s biomarker-adjusted Phase 2 analysis shows ~52pc slowing of MSA decline

Published by The Mercury · Australia 12 h ago

Alterity Therapeutics has presented additional analyses of its Phase 2 trial showing the 50mg twice-daily dose of its lead drug candidate ATH434 slowed functional ...

Read the full article on The Mercury Sign in to save

MediaNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.themercury.com.au)

Also worth reading

PerthNow

Major parties all flag big cuts to immigration numbers

The Age

Behind the scenes at Perth’s most controversial expo

The Conversation AU

Taylor would hold net overseas migration at annual 100,000 for two years in plan hitting students, refugees

The Canberra Times

A family's heartbreak after watching a loved one die from Australia's no.1 killer

pv magazine Australia

Aula Energy plans 1.8 GWh battery to ‘optimise’ 330 MW solar farm

The Guardian Australia